Skip to Content
Søg Menu

Novel intra-vesical drug delivery system, TAR-200, to be assessed in patients with high-risk non-muscle-invasive bladder cancer

A new study “SunRISe-1” investigates the rate of complete response in patients with high-risk non-muscle-invasive bladder cancer treated with TAR-200 and/or systemic cetrelimab.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Petros Grivas

Avelumab Maintenance Is a Standard of Care Option for Patients with Advanced Urothelial Carcinoma

/ Petros Grivas
ESMO24Blærecancer Play the Video 03:47
Joaquim Bellmunt

First-Line Maintenance Therapy with Avelumab Show Significantly Prolonged OS and PFS in Patients with Advanced Urothelial Cancer with Low Tumor Burden

/ Joaquim Bellmunt
ASCO24Blærecancer Play the Video 5:36
Ahmed Rehan

Real-World Data on Maintenance Avelumab Treatment

/ Ahmed Rehan
ASCOGU24Blærecancer Play the Video 2:14
Dag Rune Stormoen

Highlights fra ASCO GU 2024 om blærekræft i en dansk kontekst

/ Dag Rune Stormoen
ASCOGU24Blærecancer Play the Video 6:41
Petros Grivas

Long-Term Patient-Reported Outcomes Data from the JAVELIN Bladder 100 Trial in Patients with Advanced Urothelial Carcinoma

/ Petros Grivas
ASCOGU24Blærecancer Play the Video 02:14
Andrea Apolo

Results from Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma

/ Andrea Apolo
ASCOGU24Blærecancer Play the Video 02:02
Philippe Barthelemy

Real-World Data on Avelumab as 1L Maintenance Treatment

/ Philippe Barthélémy
ASCOGU24Blærecancer Play the Video 02:48
Jeanny B. Aragon-Ching

JAVELIN Bladder 100 Trial: Strong Avelumab Maintenance Efficacy in High BMI Patients

/ Jeanny B. Aragon-Ching
ASCOGU24BMIBlærecancer Play the Video 02:40
Srikala Sridhar

Promising Results for Enfortumab Vedotin in Neoadjuvant Treatment of Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

/ Srikala Sridhar
Blærecancer Play the Video 05:10

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top